Praeruptorin B treatment of RCC cells also exhibited reduced levels of p-EGFR, phosphorylated mitogen activated protein kinase (p-MEK), and phosphorylated extracellular signal-related kinase (p-ERK), and suppression of the EGFR-MEK-ERK signaling pathway. This evidence concerns the gene MAPK1 and renal cell carcinoma.